A Phase I, 3-part Study to Assess the Safety and Tolerability, Pharmacokinetics (including Food Effect) and Pharmacodynamics of Oral Doses of AZD5672 Following Single and Multiple Doses Administered for up to 28 Days in Healthy Volunteers

Study identifier:D1710C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, 3-part Study to Assess the Safety and Tolerability, Pharmacokinetics (including Food Effect) and Pharmacodynamics of Oral Doses of AZD5672 Following Single and Multiple Doses Administered for up to 28 Days in Healthy Volunteers

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 May 2006
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria